Safety comparison

Tadalafil vs Sildenafil: Which Is Safer?

Neither drug has a clear safety win. The side effects differ in kind, the serious warnings are the same, and one risk applies to both.

ED Treatments Compared editorial team · Updated · 8 min read

Sponsored

Neither drug is clearly safer. In the pooled head-to-head trials the overall adverse event rates are similar, and the serious warnings on the two labels are almost word for word the same.134 What differs is the kind of side effect: sildenafil is linked more to flushing, tadalafil more to back pain and muscle aches, and tadalafil stays in the body much longer, which matters most when something goes wrong or when another medicine is added.14 Which one carries less risk for a particular man depends on his heart, eyes, kidneys, liver and other medicines, so the choice belongs with a prescriber.

How do the common side effects compare?

The Viagra label reports reactions in 2% or more of men and more often than on placebo. In flexible-dose, as-needed trials of 734 men on Viagra and 725 on placebo, headache was 16% against 4%, flushing 10% against 1%, indigestion 7% against 2%, nasal congestion 4% against 2% and abnormal vision, mostly a color tinge, 3% against 0%.3 The Cialis label reports the same kind of table for as-needed use across eight placebo-controlled studies, and the rates rise with dose.4

ReactionViagra, flexible dose (placebo)Cialis 10 mg (placebo)Cialis 20 mg (placebo)
Headache16% (4%)311% (5%)415% (5%)4
Indigestion7% (2%)38% (1%)410% (1%)4
Flushing10% (1%)33% (1%)43% (1%)4
Back pain2% (2%)35% (3%)46% (3%)4
Muscle achesNot listed at 2% or more34% (1%)43% (1%)4
Nasal congestion4% (2%)33% (1%)43% (1%)4

These columns come from separate trials of different designs, so they show the kind of reaction each label reports, not a head-to-head ranking. For that, a meta-analysis pooled 16 trials that compared the two drugs directly. It found similar efficacy and overall adverse event rates, with back pain and myalgia more common and flushing less common on tadalafil than on sildenafil.1 The Cialis label adds that back pain or muscle pain typically began 12 to 24 hours after a dose and usually resolved within 48 hours, and that severe back pain was uncommon.4

What do pooled trials say about adverse events overall?

A 2026 network meta-analysis pooled 83 double-blind, placebo-controlled trials with 6,029 participants and compared four PDE5 inhibitors indirectly. It reported the odds of treatment-related adverse events were highest for vardenafil, followed by avanafil and sildenafil, and lowest for tadalafil, each against placebo. The authors note that wide confidence intervals mean the estimates are uncertain. Two of the authors are employed by Viatris, a sildenafil manufacturer, which the paper discloses.2 Indirect comparisons also cannot match the care of a randomized head-to-head trial, so this is a signal and not a verdict.

Does the dose or schedule change the picture?

Yes, for both. In the Viagra label's fixed-dose trials, headache was 16% on 25 mg, 21% on 50 mg and 28% on 100 mg, and abnormal vision was 11% at 100 mg against 2% at 50 mg.3 For tadalafil, once-a-day dosing has its own table: in three 12-week trials of the 2.5 and 5 mg doses, headache was 3% and 6% against 5% on placebo, and indigestion 4% and 5% against 2%.4 Our guide to daily versus as-needed tadalafil covers that schedule in more detail. A man who tolerates one dose poorly may do differently on another, which is a conversation for a prescriber.

Which has the eye and hearing warnings?

Both. Each label tells patients to stop the drug and seek medical attention for a sudden loss of vision in one or both eyes, which can be a sign of non-arteritic anterior ischemic optic neuropathy (NAION), and for sudden decrease or loss of hearing.34 The labels cite a case-crossover study that suggested about a 2-fold increase in NAION risk with PDE5 inhibitors as a class (risk estimate 2.15, 95% CI 1.06 to 4.34), and state that neither the rare reports nor the observational studies establish that the drugs cause it. Men who have had NAION before are at higher risk of a recurrence.4

A 2018 meta-analysis of five observational studies found no significantly higher NAION risk with PDE5 inhibitor use within a month overall (risk ratio 1.16, 95% CI 0.98 to 1.39), although the subgroup estimates for tadalafil (2.14) and sildenafil (2.25) were each above 1. The authors cautioned that the data were observational, NAION is rare and hard to diagnose, and confounding could not be controlled.5 Nothing in these sources separates the two drugs on this risk.

The color-vision effect is different. The Viagra label records transient, dose-related impairment of blue/green color discrimination at 100 and 200 mg, consistent with inhibition of PDE6 in the retina, and reports abnormal vision in 11% of men on 100 mg.3 The Cialis label describes the same laboratory finding for PDE5 inhibitors as a group, states that tadalafil is 700-fold more potent for PDE5 than for PDE6, and says reports of color vision changes were rare (under 0.1% of patients) across all studies.4

What risks are the same for both drugs?

Most of the serious warnings are shared, and they are the ones that decide whether either drug is safe for a given man:

  • Nitrates. Both are contraindicated with any form of organic nitrate, taken regularly or occasionally, and with guanylate cyclase stimulators such as riociguat.34 A Swedish registry study of 55,777 men with coronary artery disease taking nitrates found higher mortality among the 5,710 who also filled prescriptions for a PDE5 inhibitor (hazard ratio 1.39), an association rather than proof of cause, which fits the label's hard stop.6
  • Heart condition. Both labels say treatments for ED should not generally be used in men for whom sexual activity is inadvisable because of their cardiovascular status.34
  • Blood pressure medicines. Both can add to the blood-pressure-lowering effect of alpha-blockers, and each label advises being stable on the alpha-blocker first and starting at the lowest dose.34
  • Prolonged erection. An erection lasting more than 4 hours needs emergency care on either drug.34
  • Alcohol. The Cialis label says substantial drinking (about five units or more) with tadalafil can raise the chance of dizziness and a fast heart rate on standing.4

Our guide to sildenafil and tadalafil combination tablets explains why neither label supports taking the two together.

How does the length of action affect safety?

The Viagra label reports a terminal half-life of about 4 hours, while the Cialis label reports about 17.5 hours, and says the effect on erectile function can be seen for up to 36 hours after a dose.34 A longer window means more flexibility for some men. It also means that if a side effect appears, or if an interacting medicine is started, the drug is still present for longer. That is the reason the Cialis label caps the as-needed dose at 10 mg in men taking strong CYP3A4 inhibitors such as ketoconazole or ritonavir, no more often than every 72 hours.4 The Viagra label says to consider a 25 mg start with strong CYP3A4 inhibitors such as ketoconazole or itraconazole, and sets 25 mg as the maximum in 48 hours with ritonavir, which raised sildenafil levels 11-fold.3

A high-fat meal also matters for sildenafil: the label says it delays absorption by about an hour and lowers the peak level, while tadalafil absorption is not influenced by food.34 See sildenafil versus tadalafil for the full label comparison.

Which one might a prescriber lean toward?

Nobody can answer that from a table, but the sources do point to questions a clinician weighs:

  • A history of back pain or muscle problems, or reactions to a past tadalafil dose, may favor sildenafil; frequent flushing or headaches on sildenafil may favor tadalafil, from the side effect patterns above.1
  • Kidney or liver impairment changes the dose limits on both labels.34
  • Taking an alpha-blocker, including for prostate symptoms, calls for caution with either drug, and the Cialis label does not recommend tadalafil once a day with an alpha-blocker for prostate symptoms.4
  • The American Urological Association guideline treats PDE5 inhibitors as a standard option and frames the choice among them as shared decision-making between patient and clinician.7

What are the options besides choosing one?

OptionFormatFDA statusSafety information
Quattro (our pick, sponsored)Compounded sublingual combination of sildenafil, tadalafil, vardenafil and apomorphine8Compounded; not FDA-approved9No trial of this combination found; both labels say combinations with other PDE5 inhibitors have not been studied34
Viagra or generic sildenafilSwallowed tabletFDA-approved3Label trial tables; many randomized trials
Cialis or generic tadalafilSwallowed tablet, as needed or dailyFDA-approved4Label trial tables; many randomized trials

Our pick: Quattro from Vea Health Sponsored

Quattro is our pick in this guide because we have a financial relationship with Vea Health. That is the basis for the placement, not a safety result, and we make no claim that it is safer, faster or stronger than sildenafil, tadalafil or any other option.

Vea Health describes Quattro as a compounded sublingual dose combining sildenafil, tadalafil, vardenafil and apomorphine, prescribed only after a licensed clinician reviews a health history.8 For a comparison about safety, the point to weigh is that it contains both drugs plus two others, so the warnings on both labels apply, and the labels state that combinations of PDE5 inhibitors have not been studied.34 It is not FDA-approved: the FDA says it does not verify the safety, effectiveness or quality of compounded drugs before they reach patients.9 It suits a man who has discussed a multi-drug dissolving format with a clinician and accepts those limits; a clinician may decide a single approved drug is the better fit.

Questions to ask a prescriber

  • Do any of my medicines contain a nitrate, or are any of them alpha-blockers or strong CYP3A4 inhibitors?
  • Do my heart, eyes, kidneys or liver change which drug or dose is appropriate?
  • Have I had a past reaction to a PDE5 inhibitor, such as back pain, vision changes or flushing?
  • Is the product FDA-approved or compounded, and what is the evidence for that exact product? See compounded versus FDA-approved ED medications.

Safety information

Sildenafil and tadalafil must never be taken with nitrates in any form or with riociguat. An erection lasting more than four hours needs emergency care, as does sudden vision or hearing loss.34 Only a licensed clinician who knows your history and medicines can say whether either drug is appropriate.

Important safety information. PDE5 inhibitors (sildenafil, tadalafil, vardenafil) must not be taken with nitrates in any form, including nitroglycerin, or with guanylate cyclase stimulators such as riociguat, and need caution with alpha-blockers.3 The most common side effects are headache and flushing.3 An erection lasting more than four hours needs emergency care.4 Apomorphine commonly causes nausea.10 Only a licensed clinician who knows your health history and medications should decide whether any of these are safe for you.

Frequently asked questions

Is tadalafil safer than sildenafil?

Not clearly. A meta-analysis of 16 head-to-head trials found similar overall adverse event rates. Tadalafil had more back pain and muscle aches and less flushing than sildenafil. An indirect 2026 analysis found the lowest odds of treatment-related adverse events with tadalafil, with wide confidence intervals.

Do sildenafil and tadalafil have the same serious warnings?

Largely yes. Both labels contraindicate nitrates and riociguat, warn about an erection over 4 hours, sudden vision loss (possible NAION) and sudden hearing loss, and advise caution with alpha-blockers and in men whose heart condition makes sex inadvisable.

Which has more vision side effects?

The Viagra label reports abnormal vision, mostly a color tinge, in 11% of men on 100 mg in fixed-dose trials. The Cialis label reports color vision changes in under 0.1% of patients across all studies. The two are separate trial programs, not a head-to-head test.

Does tadalafil last longer, and is that a safety issue?

The Cialis label reports a half-life of about 17.5 hours and improved erectile function for up to 36 hours, against about 4 hours for sildenafil. A longer window means a side effect or interaction can last longer too, which is why the label sets lower caps with some medicines.

Is Quattro safer than either?

No evidence says so, and we make no such claim. Quattro is a compounded combination that is not FDA-approved, and both PDE5 labels say combinations of these drugs have not been studied.

More comparisons

Part of our guide: ED Pills Compared: Sildenafil, Tadalafil, Vardenafil and Avanafil

Sources

  1. Gong B, et al. Direct comparison of tadalafil with sildenafil for the treatment of erectile dysfunction: a systematic review and meta-analysis. Int Urol Nephrol. 2017. PubMed 28741090.
  2. Salonia A, et al. A comparative evaluation of on-demand phosphodiesterase-5 inhibitor efficacy in erectile dysfunction treatment: a systematic review and network meta-analysis of double-blind, placebo-controlled, randomized trials. J Sex Med. 2026. PubMed 42296271.
  3. Pfizer. VIAGRA (sildenafil citrate) prescribing information. DailyMed, U.S. National Library of Medicine.
  4. Eli Lilly. CIALIS (tadalafil) prescribing information. DailyMed, U.S. National Library of Medicine.
  5. Liu B, et al. The association between phosphodiesterase type 5 inhibitor use and risk of non-arteritic anterior ischemic optic neuropathy: a systematic review and meta-analysis. Sex Med. 2018. PubMed 29884471.
  6. Trolle Lagerros Y, et al. Risk of death in patients with coronary artery disease taking nitrates and phosphodiesterase-5 inhibitors. J Am Coll Cardiol. 2024. PubMed.
  7. American Urological Association. Erectile Dysfunction (ED) Guideline.
  8. Vea Health. Quattro. Accessed October 22, 2026.
  9. U.S. Food and Drug Administration. Compounding and the FDA: Questions and Answers.
  10. Dula E, et al. Double-blind, crossover comparison of 3 mg apomorphine SL with placebo and with 4 mg apomorphine SL in male erectile dysfunction. Eur Urol. 2001. PubMed 11464037.